A study of ENV1105 for the treatment of diabetic macular oedema (DME).

Trial Profile

A study of ENV1105 for the treatment of diabetic macular oedema (DME).

Planning
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Mar 2016 New trial record
    • 23 Mar 2016 According to an Envisia Therapeutics media release, the company expects to initiate this phase I trial of ENV1105 for the treatment of diabetic macular oedema in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top